Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia

Ladenson, Paul W.; Kristensen, Jens D.; Ridgway, E. Chester; Olsson, Anders; Carlsson, Bo; Klein, Irwin; Baxter, John D.; Angelin, Bo

doi:10.1056/nejmoa0905633

Cited by 268 publications

(123 citation statements)

References 36 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…Eprotirome induced a 23-29% reduction in serum LDL cholesterol, a 22-38% decline in serum triglyceride, and a 37-45% decrease in lipoprotein(a) in patients with hypercholesterolemia who were already receiving simvastatin or atorvastatin, but still had serum LDL levels above 116 mg/dl (182). The drug had no adverse effects on the cardiovascular system or on bone mineral turnover.…”

Section: Thyroid Hormone As a Potential Treatment For Obesitymentioning

confidence: 92%

MECHANISMS IN ENDOCRINOLOGY: The crosstalk between thyroid gland and adipose tissue: signal integration in health and disease

Santini

Marzullo

Rotondi

et al. 2014

European Journal of Endocrinology

192

170

View full text Add to dashboard Cite

Obesity and thyroid diseases are common disorders in the general population and they frequently occur in single individuals. Alongside a chance association, a direct relationship between 'thyroid and obesity' has been hypothesized. Thyroid hormone is an important determinant of energy expenditure and contributes to appetite regulation, while hormones and cytokines from the adipose tissue act on the CNS to inform on the quantity of energy stores. A continuous interaction between the thyroid hormone and regulatory mechanisms localized in adipose tissue and brain is important for human body weight control and maintenance of optimal energy balance. Whether obesity has a pathogenic role in thyroid disease remains largely a matter of investigation. This review highlights the complexity in the identification of thyroid hormone deficiency in obese patients. Regardless of the importance of treating subclinical and overt hypothyroidism, at present there is no evidence to recommend pharmacological correction of the isolated hyperthyrotropinemia often encountered in obese patients. While thyroid hormones are not indicated as anti-obesity drugs, preclinical studies suggest that thyromimetic drugs, by targeting selected receptors, might be useful in the treatment of obesity and dyslipidemia.

show abstract

Section: Thyroid Hormone As a Potential Treatment For Obesitymentioning

confidence: 92%

MECHANISMS IN ENDOCRINOLOGY: The crosstalk between thyroid gland and adipose tissue: signal integration in health and disease

Santini

Marzullo

Rotondi

et al. 2014

European Journal of Endocrinology

192

170

View full text Add to dashboard Cite

show abstract

“…For example, the TRb selective agonist GC-1 concentrates preferentially in the liver as opposed to heart, skeletal muscle, or brain (310). The KB family of molecules (i.e., KB-141 and KB-2115) has been used successfully in animals (317-320) and in hypercholesterolemic patients kept on statins to lower serum cholesterol even further while sparing the heart and bone (321,322). In these patients there were only minimal alterations in thyroid function tests.…”

Section: And Recommendation 29mentioning

confidence: 99%

American Thyroid Association Guide to Investigating Thyroid Hormone Economy and Action in Rodent and Cell Models

Bianco

Anderson

Forrest

et al. 2014

Thyroid

166

105

View full text Add to dashboard Cite

“…In a 12-week trial of eprotirome, a thyroid hormone analogue, LDL-C levels were reduced by 7-32% in males and similar reductions were observed in levels of serum ApoB, TGs, and lipoprotein(a). No substantial hepatic or muscle dysfunction was observed [45].…”

Section: Thyroid Hormone Mimeticsmentioning

confidence: 92%

New Frontiers in the Treatment of Diabetic Dyslipidemia

Wang

Hsieh

et al. 2013

Rev Diabet Stud

View full text Add to dashboard Cite

■ AbstractDyslipidemia is a major risk factor for cardiovascular complications in people with diabetes. Lowering low-density lipoprotein cholesterol (LDL-C) levels is effective in the primary and secondary prevention of diabetic vascular complications. However, LDL-C levels do not reflect all aspects of diabetic dyslipidemia, which is characterized by hypertriglyceridemia and low high-density lipoprotein cholesterol (HDL-C). Statins, nicotinic acid, and fibrates play a role in treating diabetic dyslipidemia. Atherosclerosis is a major disorder of the blood vessel wall in patients with diabetes. A number of antihyperlipidemic agents may be beneficial and exhibit effects at the actual site of vascular disease and not only on plasma lipoprotein concentrations. Several novel therapeutic compounds are currently being developed. These include additional therapeutics for LDL-C, triglycerides, HDL-C, and modulators of inflammation that can be used as possible synergic agents for the treatment of atherosclerosis and irregularities in plasma lipoprotein concentrations.

show abstract

Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia

Abstract: In this 12-week trial, the thyroid hormone analogue eprotirome was associated with decreases in levels of atherogenic lipoproteins in patients receiving treatment with statins. (ClinicalTrials.gov number, NCT00593047.)

Cited by 268 publications

References 36 publications

MECHANISMS IN ENDOCRINOLOGY: The crosstalk between thyroid gland and adipose tissue: signal integration in health and disease

MECHANISMS IN ENDOCRINOLOGY: The crosstalk between thyroid gland and adipose tissue: signal integration in health and disease

American Thyroid Association Guide to Investigating Thyroid Hormone Economy and Action in Rodent and Cell Models

New Frontiers in the Treatment of Diabetic Dyslipidemia

Contact Info

Product

Resources

About